{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:06:25Z","timestamp":1786917985777,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Nivolumab is a programmed death 1 (PD-1) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of eight different cancers including metastatic melanoma. Immune checkpoint blockade may lead to a range of neurologic immune-related adverse events (irAEs) with severity varying from mild to life-threatening, including encephalitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We describe a case of a 68-year-old man who developed alteration in mental status, physical weakness and fatigue after nine cycles of nivolumab 3 mg\/kg every two weeks. These symptoms were compatible with a clinical diagnosis of autoimmune limbic encephalitis, although no specific antibodies were detected and the initial MRI was normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient received intravenous methylprednisolone 1 g daily for 5 days, which was then converted to a maintenance dose of oral prednisone. The patient made a full clinical recovery but relapsed clinically upon steroid tapering, while hypersignal in the left mesial temporal suggestive of limbic encephalitis was observed on repeated MRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Because of the prevailing usage of nivolumab in many cancer protocols, this case highlights the importance of rapidly recognising neurological impairment in patients treated with nivolumab and of initiating very high doses of corticosteroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220904147","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T03:58:36Z","timestamp":1581911916000},"page":"1538-1543","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-1821","authenticated-orcid":false,"given":"Vincent-Thierry","family":"Taillefer","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada"},{"name":"Department of Pharmacy, Centre hospitalier de l'Universite de Montreal, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Pigeon","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Chen","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Canada"},{"name":"CHUM Research Center, CHUM, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Florescu","sequence":"additional","affiliation":[{"name":"CHUM Research Center, CHUM, Montr\u00e9al, Canada"},{"name":"Division of Hematology-Oncology, CHUM, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"B\u00e9langer","sequence":"additional","affiliation":[{"name":"CHUM Research Center, CHUM, Montr\u00e9al, Canada"},{"name":"Division of Hematology-Oncology, CHUM, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-0944","authenticated-orcid":false,"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Centre hospitalier de l'Universite de Montreal, Montreal, Canada"},{"name":"CHUM Research Center, CHUM, Montr\u00e9al, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"bibr1-1078155220904147","volume-title":"Opdivo (nivolumab) injection for intravenous infusion prescribing information","author":"Bristol-Myers Squibb","year":"2018"},{"key":"bibr2-1078155220904147","volume-title":"Opdivo product monograph","author":"Bristol-Myers Squibb Canada","year":"2019"},{"key":"bibr3-1078155220904147","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.52"},{"key":"bibr4-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183"},{"key":"bibr5-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"bibr6-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"bibr7-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1110.1110"},{"key":"bibr8-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"bibr9-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712"},{"key":"bibr10-1078155220904147","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00706"},{"key":"bibr11-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1177\/1758834018757175"},{"key":"bibr12-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"bibr13-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1159\/000477162"},{"key":"bibr14-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"bibr15-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729069"},{"key":"bibr16-1078155220904147","volume":"2018","author":"Shah S","year":"2018","journal-title":"Case Rep Neurol Med"},{"key":"bibr17-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"bibr18-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.23.4.jnp384"},{"key":"bibr19-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9183979"},{"key":"bibr20-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0533-0"},{"key":"bibr21-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12607"},{"key":"bibr22-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.038"},{"key":"bibr23-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"bibr24-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1399"},{"key":"bibr25-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr26-1078155220904147","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0047"},{"key":"bibr27-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"bibr28-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.009"},{"key":"bibr29-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.03.007"},{"key":"bibr30-1078155220904147","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0507"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220904147","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220904147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:32Z","timestamp":1777688552000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220904147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1078155220904147"],"URL":"https:\/\/doi.org\/10.1177\/1078155220904147","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]}}}